Similar Papers

Paper Title
Journal
Date
Author
Real-world switching and discontinuation outcomes of infliximab biosimilars in patients with rheumatoid arthritis: A scoping review.
Yue Yin ... Cara Mcdermott
Journal of managed care & specialty pharmacy | VOL. 29
Yue Yin, et. al.Yue Yin ... Cara Mcdermott
01 Sep 2023
Effectiveness of non-medical switch from adalimumab bio-originator to SB5 biosimilar and from ABP501 adalimumab biosimilar to SB5 biosimilar in patients with chronic inflammatory arthropathies: a monocentric observational study.
Rossana Scrivo ... Valeria Riccieri
Clinical and Experimental Rheumatology | VOL. 41
Rossana Scrivo, et. al.Rossana Scrivo ... Valeria Riccieri
21 Jan 2022
Comparative efficacy and safety of infliximab and its biosimilars in patients with rheumatoid arthritis presenting an insufficient response to methotrexate : Anetwork meta-analysis.
Young Ho Lee ... Gwan Gyu Song
Zeitschrift für Rheumatologie | VOL. 82
Young Ho Lee, et. al.Young Ho Lee ... Gwan Gyu Song
06 Jul 2021
Discontinuation of biosimilar infliximab in Japanese patients with rheumatoid arthritis achieving sustained clinical remission or low disease activity during the IFX-SIRIUS STUDY I (the IFX-SIRIUS STUDY II): Study protocol for an interventional, multicenter, open-label, single-arm clinical trial with clinical, ultrasound and biomarker assessments.
Toshimasa Shimizu ... Remi Sumiyoshi
Medicine | VOL. 99
Toshimasa Shimizu, et. al.Toshimasa Shimizu ... Remi Sumiyoshi
07 Aug 2020
View more papers

More From: Value in Health

Paper Title
Journal
Date
Author
Table of Contents
-
Value in Health | VOL. 28
--
01 Feb 2025
Editorial Board
-
Value in Health | VOL. 28
--
01 Feb 2025
Table of Contents
-
Value in Health | VOL. -
--
01 Jan 2025
Good Practices for Health Technology Assessment Guideline Development: A Report of the Health Technology Assessment International, HTAsiaLink, and ISPOR Special Task Force
Siobhan Botwright ... Yot Teerawattananon
Value in Health | VOL. -
Siobhan Botwright, et. al.Siobhan Botwright ... Yot Teerawattananon
01 Jan 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.